Navigation Links
Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex

wo-pronged phase 2/3 clinical approach for Ceflatonin, targeting Gleevec-resistant CML patients who harbour the T315I mutation, as well as CML patients who have failed two tyrosine kinase inhibitors (usually Gleevec and Sprycel).

Gleevec(R)/Glivec(R) is a registered trademark of Novartis AG.

Sprycel(R) is a registered trademark of the Bristol-Myers Squibb Company.

Ceflatonin(R) is a registered trademark of ChemGenex Pharmaceuticals Limited.

About ChemGenex Pharmaceuticals Limited (www.chemgenex.com)

ChemGenex Pharmaceuticals is a pharmaceutical development company dedicated to improving the lives of patients by developing therapeutics in the areas of oncology, diabetes, obesity, and depression. ChemGenex harnesses the power of genomics for target discovery and validation, and in clinical trials to develop more individualized therapeutic outcomes. ChemGenex's lead compound, Ceflatonin(R), is currently in phase 2/3 clinical trials for chronic myeloid leukemia (CML) and Quinamed(R) is in phase 2 clinical development for prostate, breast and ovarian cancers. The company has a significant portfolio of anti-cancer, diabetes, obesity and depression programs, several of which have been partnered with international pharmaceutical companies. ChemGenex currently trades on the Australian Stock Exchange under the symbol "CXS" and on NASDAQ under the symbol "CXSP".

Safe Harbor Statement

Certain statements made herein that use the words "estimate", "project", "intend", "expect", "believe", and similar expressions are intended to identify forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties which could cause the actual results, performance or achievements of the company to be materially different from those which may be expressed or implied by such statements, including, among others, risks or uncert
'"/>




Page: 1 2 3

Related medicine technology :

1. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
2. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
3. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
4. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
5. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
6. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
7. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
8. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
9. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
10. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
11. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
Post Your Comments:
(Date:9/2/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... on tissue protection, repair and regeneration, today announced ... Executive Officer, will present a corporate overview at ... by H.C. Wainwright & Co.  The ... the St. Regis Hotel in New York City.   ...
(Date:9/2/2015)... Sept. 2, 2015  MGC Diagnostics Corporation (NasdaqCM: MGCD), ... call to discuss its financial results for the third ... call will be at 4:30 p.m. ET on Thursday, ... for the third quarter of fiscal 2015 after the ... Participants can dial (877) 317-6789 or (412) 317-6789 ...
(Date:9/2/2015)... Sept. 2, 2015 Relmada Therapeutics, Inc. (OTCQB: ... the treatment of chronic pain, announced today that the ... the FBR Second Annual Healthcare Conference and BioCentury NewsMakers ... FBR Second Annual Healthcare Conference Date:  Wednesday, ... No presentation, investor meetings only ...
Breaking Medicine Technology:RegeneRx to Present at Rodman & Renshaw Global Investment Conference 2RegeneRx to Present at Rodman & Renshaw Global Investment Conference 3MGC Diagnostics Corporation to Report Third Quarter Fiscal 2015 Financial Results on Thursday, September 10, 2015 2Relmada Therapeutics to Participate in Two Upcoming Investor Conferences 2
... ECRI Institute(R) Evidence Report Compares Effectiveness of CT ... The value of CT colonography, also ... considers halting coverage of these procedures as a ... growths. Research findings from meta-analyses performed by ECRI ...
... being issued by Coast IRB: In a ... the public that it had discovered what appeared to be ... for evaluation. Coast IRB has since learned that the ... "sting" operation. Apparently at the behest of the U.S. ...
Cached Medicine Technology:Virtual Colonoscopies Show Value for Some Patients, But Polyps Will Be Missed 2Virtual Colonoscopies Show Value for Some Patients, But Polyps Will Be Missed 3Congressional 'Sting' Operation Uncovered By Coast IRB 2
(Date:9/2/2015)... ... September 02, 2015 , ... The Hydration ... allopathic medicine, opens its second location this week at 31542 S. Coast Hwy, ... feet of lounge space for patients to relax while receiving safe and effective ...
(Date:9/2/2015)... Burnsville, MN (PRWEB) , ... September 02, 2015 , ... ... forward to it; others dread it. However, few are prepared to face the academic ... once school starts. Our schools haven’t prepared them since schools don’t teach students how ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... the upper extremity surgical market, announced today that more than 600 successful patient ... in the hand. Plus, nearly 70 of these procedures have been on ...
(Date:9/2/2015)... ... September 02, 2015 , ... Lakeview Health, a nationally recognized ... Overdose Awareness Day. The goal is to provide people information regarding drugs and ... they may get help. , Lakeview Health will be publishing information ...
(Date:9/2/2015)... PA (PRWEB) , ... September 02, 2015 , ... Pentec ... prestigious 2015 Inc. 5000 List for an impressive sixth consecutive year. Less than 5 ... with only twelve firms in the “health” sector. Pentec’s 3-year revenue growth rate ...
Breaking Medicine News(10 mins):Health News:The Hydration Room Opens New Location In Laguna Beach, California 2Health News:The Hydration Room Opens New Location In Laguna Beach, California 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 4Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3Health News:Trigger Tome Surpasses 600 Successful Patient Procedures 2Health News:August 31 is International Overdose Awareness Day – Lakeview Health to Help Bring Awareness 2Health News:Pentec Health Once Again Named One of the Fastest-Growing Private Companies in America 2
... Tenn., Jan. 13 The National Eczema Association,(NEA) awarded ... Lotion. , The NEA Seal ... Education (EASE) program, which is intended to improve the,quality ... eczema and sensitive,skin. , "These ...
... now open for a more rewarding challenge , ... Jenkintown, PA (PRWEB) January 13, 2009 ... resolutions and according to USA.gov, losing weight and getting fit are among the ... many of those eager to fulfill their vows is to lace up their ...
... to meet their customers, product needs quickly and efficiently, Nationwide Medical/Surgical ... 2009-2010 season beginning in August. , ... (Vocus) January ... the Flu Vaccine for the 2009-2010 flu season. ...
... persistence to seek out the best treatment options available ... leg today. Bill,s proactive efforts led him to revolutionary ... Methodist Hospital, in Columbus, Ohio, where a team of ... During the minimally invasive procedure, they also found and ...
... announces the launch of their new website www.GlaceComplete.com . ... to Glenwood Systems and the company,s turbo-charged practice management/billing system GlaceComplete ... information. , ... Waterbury, CT (PRWEB) January Monday 12, ...
... of the 21,000 Americans who die each year of ... likely cause. So, the American Association of ... Cancer Survivors Against Radon (CanSAR) with a ... those who never smoked. Those making the connection, along ...
Cached Medicine News:Health News:National Eczema Association Anoints Theraplex Child-Friendly Eczema Products with Seal of Acceptance 2Health News:The Breast Cancer 3-Day Challenges Americans to Get Out of the New Year's Resolution Rut 2Health News:The Breast Cancer 3-Day Challenges Americans to Get Out of the New Year's Resolution Rut 3Health News:The Breast Cancer 3-Day Challenges Americans to Get Out of the New Year's Resolution Rut 4Health News:Nationwide Medical/Surgical Announces They Will Carry Flu Vaccine 2Health News:Irishman with Peripheral Arterial Disease (P.A.D.) Finds Leg-, Life-Saving Treatment In Columbus, Ohio 2Health News:Irishman with Peripheral Arterial Disease (P.A.D.) Finds Leg-, Life-Saving Treatment In Columbus, Ohio 3Health News:Irishman with Peripheral Arterial Disease (P.A.D.) Finds Leg-, Life-Saving Treatment In Columbus, Ohio 4Health News:Glenwood Systems, LLC Launches New Website -- GlaceComplete.com 2Health News:Program to Identify Likely Victims of Radon-Related Lung Cancer; Survivors Commit to Risk Reduction Despite Failed Government Policy 2Health News:Program to Identify Likely Victims of Radon-Related Lung Cancer; Survivors Commit to Risk Reduction Despite Failed Government Policy 3Health News:Program to Identify Likely Victims of Radon-Related Lung Cancer; Survivors Commit to Risk Reduction Despite Failed Government Policy 4
... protein 4 (IGFBP-4) is a 24 kDa protein ... IGF-I and IGF-II. It is also present in ... 28 kDa. IGFBP-4 has been identified in all ... types, including fibroblasts, neuroblastoma, prostate and bone cells ...
... the adrenal gland and gonads, is the ... both of which may be subsequently converted ... activity, estimated at ~(less than or equal ... androstenedione levels often exceed testosterone in both ...
... Inhibins are heterodimeric proteins that suppress ... from the pituitary. Inhibin consists of two ... linked together. Inhibin A consists of the ... the alpha-subunit and betaB-subunit. Only the dimeric ...
... a 7.5 kDa peptide which is secreted primarily ... mitogenic and metabolic actions involved in cellular growth. ... to target cell receptors. IGF-II binds with high ... monomeric protein which also serves as the receptor ...
Medicine Products: